Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member γ, but not α or δ

Carcinogenesis

Volumn 26, Issue 10, 2005, Pages 1782-1792

  Knight, Belinda ^a,c   Yeap, Bu ^a,c   Yeoh, George C ^b,c   Olynyk, John K ^a,c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CHOLINE; CIGLITAZONE; ETHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL COUNT; CELL GROWTH; CELL IMMORTALIZATION; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CELL VIABILITY; CHRONIC LIVER DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; FATTY LIVER; GENE EXPRESSION; GENETIC VARIABILITY; GROWTH INHIBITION; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; STEM CELL; VITAMIN DEFICIENCY;

ANIMALS; CELL DIVISION; CELL LINE; CELL SURVIVAL; ETHIONINE; LIVER; MALE; MICE; MICE, INBRED C57BL; PPAR ALPHA; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEM CELLS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 27144555677     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi138     Document Type: Article

References (60)

1. Lowes,X.N., Croager,E.J., Olynyk,J.K., Abraham,L.J. and Yeoh,G.C. (2003) Oval cell-mediated liver regeneration: Role of cytokines and growth factors. J. Gastroenterol. Hepatol., 18, 4-12.
2. Roskams,T.A., Libbrecht,L. and Desmet,V.J. (2003) Progenitor cells in diseased human liver. Semin. Liver Dis., 23, 385-396.
3. Fausto,N. and Campbell,J.S. (2003) The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech. Dev., 120, 117-130.
4. Hadjiolov,N. and Bitsch,A. (1997) Early effects in chemical-induced rat liver carcinogenesis: An immunohistochemical study following exposure to 0.04% AAF. Apoptosis, 2, 91-100.
5. Oh,B.K., Lee,C.H., Park,C. and Park,Y.N. (2004) Telomerase regulation and progressive telomere shortening of rat hepatic stem-like epithelial cells during in vitro aging. Exp. Cell Res., 298, 445-454.
6. Knight,B., Matthews,V.B., Akhurst,B., Croager,E.J., Abraham,L.J., Olynyk,J.K. and Yeoh,G.C. (2005) Inflammation and cytokine, production, but not acute phase protein synthesis, accompany the liver progenitor (oval) cell response to chronic liver injury. Immunol. Cell Biol., in press.
7. Lowes,X.N., Brennan,B.A., Yeoh,G.C. and Olynyk,J.K. (1999) Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am. J. Pathol., 154, 537-541.
8. Hacker,H.J., Steinberg,P., Toshkov,I., Oesch,F. and Bannasch,P. (1992) Persistence of the cholangiocellular and hepatocellular lesions observed in rats fed a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis, 13, 271-276.
9. Fang,C.H., Gong,J.Q. and Zhang,W. (2004) Function of oval cells in hepatocellular carcinoma in rats. World J. Gastroenterol., 10, 2482-2487.
10. Goyette,M., Faris,R., Braun,L., Hixson,D. and Fausto,N. (1990) Expression of hepatocyte and oval cell antigens in hepatocellular carcinomas produced by oncogene-transfected liver epithelia] cells. Cancer Res., 50, 4809-4817.
11. Dumble,M.L., Croager,E.J., Yeoh,G.C. and Quail,E.A. (2002) Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis, 23, 435-445.
12. Tan,E., Besant,P.G., Zu,X.L., Turck,C.W., Bogoyevitch,M.A., Lim,S.G., Attwood,P.V. and Yeoh,G.C. (2004) Histone H4 histidine kinase displays the expression pattern of a liver oncodevelopmental marker. Carcinogenesis, 25, 2083-2088.
13. Yaswen,P., Thompson,N.L. and Fausto,N. (1985) Oncodevelopmental expression of rat placental alkaline phosphatase. Detection in oval cells during liver carcinogenesis. Am. J. Pathol., 121, 505-513.
14. Yaswen,P., Goyette,M., Shank,P.R. and Fausto,N. (1985) Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis. Mol. Cell Biol., 5, 780-786.
15. Knight,B., Yeoh,G.C., Husk,K.L., Ly,T., Abraham,L.J., Yu,C., Rhim,J.A. and Fausto,N. (2000) Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med., 192, 1809-1818.
16. Qi,C., Zhu,Y. and Reddy,J.K. (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem. Biophys., 32, 187-204.
17. Ferre,P. (2004) The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes, 53 (Suppl. 1), S43-S50.
18. Braissant,O., Foufelle,F., Scotto,C., Dauca,M. and Wahli,W. (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 137, 354-366.
19. Walgen,J.E., Kurtz,D.T. and McMillan,J.M. (2000) Expression of PPAR(alpha) in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res. Commun. Mol. Pathol. Pharmacol., 108, 116-132.
20. Roberts,R.A., Chevalier,S., Hasmall,S.C., James,N.H., Cosulich,S.C. and Macdonald,N. (2002) PPAR alpha and the regulation of cell division and apoptosis. Toxicology, 181-182, 167-170.
21. Marsman,D.S., Cattley,R.C., Conway,J.G. and Popp,J.A. (1988) Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in rats. Cancer Res., 48, 6739-6744.
22. Anderson,S.P., Dunn,C.S., Cattley,R.C. and Corton,J.C. (2001) Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling. Carcinogenesis, 22, 1843-1851.
23. Anderson,S.P., Yoon,L., Richard,E.B., Dunn,C.S., Cattley,R.C. and Corton,J.C. (2002) Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology, 36, 544-554.
24. Rao,M.S., Peters,J.M., Gonzalez,F.J. and Reddy,J.K. (2002) Hepatic regeneration in peroxisome proliferator-activated receptor alpha-null mice after partial hepatectomy. Hepatol. Res., 22, 52-57.
25. Rao,M.S. and Reddy,J.K. (1996) Hepatocarcinogenesis of peroxisome proliferators. Ann. N. Y. Acad. Sci., 804, 573-587.
26. Lawrence,J.W., Li,Y., Chen,S., DeLuca,J.G., Berger,J.P., Umbenhauer,D.R., Moller,D.E. and Zhou,G. (2001) Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J. Biol. Chem., 276, 31521-31527.
27. Marra,F., Efsen,E., Romanelli,R.G. et al. (2000) Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and pro-inflammatory actions in hepatic stellate cells. Gastroenterology, 119, 466-478.
28. Uchimura,K., Nakamuta,M., Enjoji,M., Irie,T., Sugimoto,R., Muta,T., Iwamoto,H. and Nawata,H. (2001) Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology, 33, 91-99.
29. Li,M.Y., Deng,H., Zhao,J.M., Dai,D. and Tan,X.Y. (2003) Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. World J. Gastroenterol., 9, 1683-1688.
30. Li,M.Y., Deng,H., Zhao,J.M., Dai,D. and Tan,X.Y. (2003) PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J. Gastroenterol., 9, 1220-1226.
31. Cheng,J., Nakamura,H., Imanishi,H., Liu,W., Morisaki,T., Sugiyama,T. and Hada,T. (2004) Peroxisome proliferator-activated receptor gamma ligands, 15-deoxy-Delta 12,14-prostaglandin J2, and ciglitazone, induce growth inhibition and cell cycle arrest in hepatic oval cells. Biochem. Biophys. Res. Commun., 322, 458-464.
32. Kawaguchi,K., Sakaida,I., Tsuchiya,M., Omori,K., Takami,T. and Okita,K. (2004) Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem. Biophys. Res. Commun., 315, 187-195.
33. Promrat,K., Lutchman,G., Uwaifo,G.I. et al. (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 39, 188-196.
34. Hellemans,K., Michalik,L., Dittie,A. et al. (2003) Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology, 124, 184-201.
35. Glinghammar,B., Skogsberg,J., Hamsten,A. and Ehrenborg,E. (2003) PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun., 308, 361-368.
36. Wang,Y.X., Lee,C.H., Tiep,S., Yu,R.T., Ham,J., Kang,H. and Evans,R.M. (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell, 113, 159-170.
37. Akhurst,B., Croager,E.J., Farley-Roche,C.A., Ong,J.K., Dumble,M.L., Knight,B. and Yeoh,G.C. (2001) A modified choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse liver. Hepatology, 34, 519-522.
38. Matthews,V.B., Klinken,E. and Yeoh,G.C. (2004) Direct effects of interleukin-6 on liver progenitor oval cells in culture. Wound Repair Regen., 12, 650-656.
39. Matthews,V.B., Knight,B., Tirnitz-Parker,J.E.E., Boon,J., Olynyk,J.K. and Yeoh,G.C. (2005) Oncostatin M induces an acute phase response, but does not modulate the growth or maturation-status of liver progenitor (oval) cells in culture. Exp. Cell Res., 306, 252-263.
40. Denizot,F. and Lang,R. (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods, 89, 271-277.
41. Towers,B. (1953) A modification of Masson's trichrome stain which differentiates in colour between striated and smooth muscle. J. Physiol., 119, 23P-24P.
42. Leicester,K.L., Olynyk,J.K., Brunt,E.M., Britton,R.S. and Bacon,B.R. (2004) CD14-positive hepatic monocytes/macrophages increase in hereditary hemochromatosis. Liver Int., 24, 446-451.
43. Honda,K., Marquillies,P., Capron,M. and Dombrowicz,D. (2004) Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J. Allergy Clin. Immunol., 113, 882-888.
44. Lebovic,D.I., Kir,M. and Casey,C.L. (2004) Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil. Steril., 81 (Suppl. 3), 1008-1013.
45. Gupta,R.A., Wang,D., Katkuri,S., Wang,H., Dey,S.K. and DuBois,R.N. (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nature Med., 10, 245-247.
46. Fajas,L., Auboeuf,D., Raspe,E. et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 272, 18779-18789.
47. Stephen,R.L., Gustafsson,M.C., Jarvis,M., Tatoud,R., Marshall,B.R., Knight,D., Ehrenborg,E., Harris,A.L., Wolf,C.R. and Palmer,C.N. (2004) Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res., 64, 3162-3170.
48. Hasmall,S.C., James,N.H., Macdonald,N., West,D., Chevalier,S., Cosulich,S.C. and Roberts,R.A. (1999) Suppression of apoptosis and induction of DNA synthesis in vitro by the phthalate plasticizers monoethylhexylphthalate (MEHP) and diisononylphthalate (DINP): A comparison of rat and human hepatocytes in vitro. Arch. Toxicol., 73, 451-456.
49. Mounho,B.J. and Thrall,B.D. (1999) The extracellular signal-regulated kinase pathway contributes to mitogenic and antiapoptotic effects of peroxisome proliferators in vitro. Toxicol. Appl. Pharmacol., 159, 125-133.
50. Plant,N.J., Horley,N.J., Dickins,M., Hasmall,S., Elcombe,C.R. and Bell,D.R. (1998) The coordinate regulation of DNA synthesis and suppression of apoptosis is differentially regulated by the liver growth agents, phenobarbital and methylclofenapate. Carcinogenesis, 19, 1521-1527.
51. Kaplanski,C., Pauley,C.J., Griffiths,T.G., Kawabata,T.T. and Ledwith,B.J. (2000) Differentiation of rat oval cells after activation of peroxisome proliferator-activated receptor alpha43. Cancer Res., 60, 580-587.
52. Desvergne,B., Michalik,L. and Wahli,W. (2004) Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol. Endocrinol., 18, 1321-1332.
53. Cuzzocrea,S., Pisano,B., Dugo,L. et al. (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med., 30, 951-956.
54. Enomoto,N., Takei,Y., Hirose,M., Konno,A., Shibuya,T., Matsuyama,S., Suzuki,S., Kitamura,K.I. and Sato,N. (2003) Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J. Pharmacol. Exp. Ther., 306, 846-854.
55. Ohata,M., Suzuki,H., Sakamoto,K., Hashimoto,K,, Nakajima,H., Yamauchi,M., Hokkyo,K., Yamada,H. and Toda,G. (2004) Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. Alcohol Clin. Exp. Res., 28, 139S-144S.
56. Galli,A., Crabb,D.W., Ceni,E., Salzano,R., Mello,T., Svegliati-Baroni,G., Ridolfi,F., Trozzi,L., Suffenti,C. and Casini,A. (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 122, 1924-1940.
57. Yuan,G.J., Zhang,M.L. and Gong,Z.J. (2004) Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J. Gastroenterol., 10, 1047-1051.
58. Kon,K., Ikejima,K., Hirose,M., Yoshikawa,M., Enomoto,N., Kitamura,T., Takei,Y. and Sato,N. (2002) Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem. Biophys. Res. Commun., 291, 55-61.
59. Tomita,K., Azuma,T., Kitamura,N., Nishida,J., Tamiya,G., Oka,A., Inokuchi,S., Nishimura, T., Suematsu, M. and Ishii, H. (2004) Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology, 126, 873-885.
60. Hockings,P.D., Changani,K.K., Saeed,N., Reid,D.G., Birmingham,J., O'Brien,P., Osborne,J., Toseland,C.N. and Buckingham,R.E. (2003) Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats. Diabetes Obes, Metab., 5, 234-243.